普拉克索治疗帕金森病运动并发症的临床疗效观察

目的 评估普拉克索治疗帕金森病运动并发症的临床疗效及安全性.方法 收集92例晚期帕金森病患者并随机分为治疗组和对照组,每组46例.对照组给予多巴丝肼治疗,治疗组在对照组的基础上给予普拉克索,疗程均为12周.两组患者于治疗前后分时间点进行统一帕金森病评定量表修正(UPDRSⅣ-)的评分、不良反应的记录,疗程结束后评估疗效.结果 治疗后对照组和治疗组UPDRSⅣ-评分与基线比较均有下降,治疗组下降更显著,两组比较差异有统计学意义(P＜0.01).治疗组第12周剂末现象(93.75％vs 70.59％)、开关现象(91.67％ vs 63.64％)以及异动症(84.62％ vs48.00％)的总有效率优于对照组,差异均有统计学意义(P＜0.05).两组不良反应发生率差异无统计学意义(P＞0.05).结论 普拉克索治疗帕金森病运动并发症有效,安全性好.

Clinical effect of pramipexole in the treatment of motor complications in Parkinson’s disease

Objective To evaluate the clinical effect and safety of pramipexole in the treatment of motor complications in Parkinson''s disease.Methods Ninety-two patients with advanced Parkinson''s disease were randomly divided into treatment group (n=46) and control group (n=46). Madopar was administered in the control group, whereas the treatment group was given pramipexole in addition to the therapy for control group. The course of treatment was 12 weeks for both groups. Unified Parkinson''s Disease Rating Scale (UPDRS) IV was used for evaluating the patients'' conditions before treatment and at different time points during treatment, and the adverse events were recorded. The clinical effects were assessed after 12 weeks of treatment.Results After treatment, UPDRS IV score decreased compared with the baseline value in both groups, and the treatment group had a significantly more decrease than the control group (P<0.01). At the end of the 12-week treatment, the treatment group had significantly higher overall response rates than the control group in terms of wearing-off phenomenon (93.75% vs 70.59%, P<0.05), on-off phenomenon (91.67% vs 63.64%, P<0.05), and dyskinesia (84.62% vs 48.00%, P<0.05). There was no significant difference in the incidence of adverse events showed no significant difference between the two groups (P>0.05).Conclusions Pramipexole has good clinical effects and safety in the treatment of motor complications in Parkinson''s disease.